Literature DB >> 21056081

Role of SHIP in cancer.

Melisa J Hamilton1, Victor W Ho, Etsushi Kuroda, Jens Ruschmann, Frann Antignano, Vivian Lam, Gerald Krystal.   

Abstract

The SH2-containing inositol-5'-phosphatase, SHIP (or SHIP1), is a hematopoietic-restricted phosphatidylinositide phosphatase that translocates to the plasma membrane after extracellular stimulation and hydrolyzes the phosphatidylinositol-3-kinase-generated second messenger PI-3,4,5-P(3) to PI-3,4-P(2). As a result, SHIP dampens down PI-3,4,5-P(3)-mediated signaling and represses the proliferation, differentiation, survival, activation, and migration of hematopoietic cells. There are multiple lines of evidence suggesting that SHIP may act as a tumor suppressor during leukemogenesis and lymphomagenesis. Because of its ability to skew macrophage progenitors toward M1 macrophages and naïve T cells toward T helper 1 and T helper 17 cells, SHIP may play a critical role in activating the immune system to eradicate solid tumors. In this review, we will discuss the role of SHIP in hematopoietic cells and its therapeutic potential in terms of suppressing leukemias and lymphomas and manipulating the immune system to combat cancer.
Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056081     DOI: 10.1016/j.exphem.2010.11.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  25 in total

Review 1.  Macrophage polarization: the link between inflammation and related diseases.

Authors:  Samina Bashir; Yadhu Sharma; Asif Elahi; Farah Khan
Journal:  Inflamm Res       Date:  2016-01       Impact factor: 4.575

2.  The role of SHIP in the development and activation of mouse mucosal and connective tissue mast cells.

Authors:  Jens Ruschmann; Frann Antignano; Vivian Lam; Kim Snyder; Connie Kim; Martha Essak; Angela Zhang; Ann Hsu-An Lin; Raghuveer Singh Mali; Reuben Kapur; Gerald Krystal
Journal:  J Immunol       Date:  2012-03-19       Impact factor: 5.422

3.  Lipid Signaling in Tumorigenesis.

Authors:  Renyan Liu; Ying Huang
Journal:  Mol Cell Pharmacol       Date:  2014-01-01

4.  Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.

Authors:  Gwenny M Fuhler; Robert Brooks; Bonnie Toms; Sonia Iyer; Elizabeth A Gengo; Mi-Young Park; Matthew Gumbleton; Dennis R Viernes; John D Chisholm; William G Kerr
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

5.  Phosphatidylinositol 3,4-bisphosphate regulates neurite initiation and dendrite morphogenesis via actin aggregation.

Authors:  Shu-Xin Zhang; Li-Hui Duan; Shun-Ji He; Gui-Feng Zhuang; Xiang Yu
Journal:  Cell Res       Date:  2017-01-20       Impact factor: 25.617

6.  Expression, Purification, Crystallisation and X-ray Crystallographic Analysis of a Truncated Form of Human Src Homology 2 Containing Inositol 5-Phosphatase 2.

Authors:  Johanne Le Coq; Luis Heredia Gallego; Daniel Lietha
Journal:  Protein J       Date:  2016-06       Impact factor: 2.371

7.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

8.  Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation.

Authors:  Nivedita Banerjee; Stephen Talcott; Stephen Safe; Susanne U Mertens-Talcott
Journal:  Breast Cancer Res Treat       Date:  2012-09-02       Impact factor: 4.872

Review 9.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

Review 10.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.